University of Houston College of Pharmacy, Houston, Texas.
Pharmacotherapy. 2013 Oct;33(10):1126-9. doi: 10.1002/phar.1308. Epub 2013 Jun 6.
To determine if development of acneiform rash is a predictor of objective response rate with lapatinib.
Subanalysis of data from a prospective, phase II study.
Academic breast care clinic.
Forty-nine treatment-naïve patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced breast cancer, who were treated with neoadjuvant lapatinib monotherapy for 6 weeks; 47 patients were included in the final analysis.
Of the 49 patients enrolled, 33 (67%) developed a rash of any type, and 26 (55%) had acneiform rash. Of the 26 evaluable patients with acneiform rash (55%), 19 (73%) responded to lapatinib and 7 (27%) did not. Of the 21 evaluable patients without acneiform rash, 11 (67%) responded to treatment and 7 (33%) did not. Thus, no association was found between the occurrence of acneiform rash and response to lapatinib monotherapy.
This study does not support the development of the acneiform rash as a predictor of clinical efficacy of lapatinib in the treatment of breast cancer.
确定痤疮样皮疹的发展是否是曲拉西利治疗客观反应率的预测指标。
前瞻性、二期研究数据的亚分析。
学术乳腺护理诊所。
49 例人表皮生长因子受体 2（HER2）阳性局部晚期乳腺癌的初治患者，接受曲拉西利新辅助单药治疗 6 周；47 例患者纳入最终分析。
在入组的 49 例患者中，33 例（67%）出现任何类型的皮疹，26 例（55%）出现痤疮样皮疹。在 26 例可评估的痤疮样皮疹患者（55%）中，19 例（73%）对曲拉西利有反应，7 例（27%）没有反应。在 21 例可评估无痤疮样皮疹的患者中，11 例（67%）对治疗有反应，7 例（33%）没有反应。因此，未发现痤疮样皮疹的发生与曲拉西利单药治疗的疗效之间存在关联。
本研究不支持痤疮样皮疹的发生作为曲拉西利治疗乳腺癌临床疗效的预测指标。
